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Introduction:  Several studies indicate a higher prevalence of fracture following long 
term utilization of proton pump inhibitors, among them omeprazole is the most 
widely used. However, the exact mechanisms lead to this complication are largely 
unknown. We studied short term effects of omeprazole on some markers of calcium 
metabolism. Materials and Methods: In thirty young adult patients with gastroe-
sophageal reflux, omeprazole was prescribed at 20 mg twice daily for thirty days. 
Baseline characteristics as well as data after treatment with omeprazole were 
compared. We also measure important parameters in sixty age and sex match healthy 
individuals at baseline. Results: Mean age of patients was 31.8 year and there was no 
significant difference regarding age, sex, body mass index, serum calcium, serum 
alkaline phosphatase and parathyroid hormone between cases and controls. Although, 
most of the patients were vitamin D deficient (mean = 29.7 nmol/l); compared to 
controls serum 25 OH Vitamin D was higher (P= 0.005) and serum phosphate was 
lower (P= 0.001) in patients. In addition, there was significant increase in alkaline 
phosphatase (P=0.01) and borderline decrease in serum calcium (P= 0.057), thirty 
days after treatment with omeprazole. Conclusions: High dose omeprazole after 
thirty days in the presence of vitamin D deficiency affects bone turnover probably by 
decreasing calcium absorption.
MATERIALS AND METHODS
criteria were: previous treatment with any gastric acid 
suppressant (e.g. PPIs, H2 blockers, Antacids), long 
duration of symptoms, use of any drug that affects bone 
and calcium metabolism (e.g. calcium, vitamin D (vit D), 
bisphosphonates, steroids), smoking, pregnancy, previous 
gastrointestinal (GI) surgery, malabsorption syndromes, 
cancers and any disorder that may disturb bone or calcium 
homeostasis e.g. renal disease. Omeprazole was prescribed 
at 20 mg twice daily on empty stomach. We conducted a 
positive pill count to ensure compliance. Thirty days after 
initiation of treatment the clinical and laboratory data were 
recorded. A control group consists of sixty age and sex 
matched healthy individuals were included in study. 5 ml 
blood was obtained at baseline (patients and controls) and 
thirty days after treatment (patients) by venipuncture. Sera 
were extracted and freezes at -80°C until further analysis.
Height and weight were measured by stadiometer and clinical 
scale and body mass index was calculated as weight/height2. 
Serum parathyroid hormone (PTH) and 25 OH vit D were 
measured by Chemiluminescent assay (CLIA) (Diasorin Inc. 
USA) with intra assay coefficients of variation less than 5%
In a prospective study thirty young otherwise, healthy adults 
with diagnosis of gastroesophageal reflux disease (GERD) 
were enrolled. Baseline clinical and laboratory characteristics 
were recorded using a structured questionnaire. Exclusion
Alkaline Phosphatase (ALP), 
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deficiency
Omeprazole is the most widely used proton pump inhibitors 
(PPIs) (1,2). Several lines of evidence indicate that there is 
higher prevalence of fracture among users of omeprazole 
(3-7). 
A number of mechanisms have been proposed to explain this 
phenomenon. Although direct effect of omeprazole on bone 
may be a plausible mechanism (8-11), the most attractive 
theory is decrease in calcium absorption due to omeprazole 
induced hypochlorhydria. In this regard, A number of studies 
showed decreased intestinal calcium absorption (12-16) while 
others not (17,18). However, the exact mechanisms by which 
omeprazole affects bone and calcium metabolism remained to 
be identified. 
The aim of present study was to determine effects of 
omeprazole on markers of calcium homeostasis in young 
adults treated for gastroesophageal reflux disease.       
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heterogeneous.
A number of studies focused on hypochlorohydric effect 
of omeprazole on intestinal calcium absorption; most of 
them showed a decrease in calcium absorption (12,13,16). 
However, these studies were of small sample size and short 
duration. 
Recently, Hansen et al. showed no statistically significant 
alteration in calcium absorption following 30 days use of 
omeprazole in postmenopausal women by calculating true 
fractional calcium absorption (TFCA) using dual isotope 
study (17). Although, isotope studies designated as standard 
mode of TFCA the calcium preparation is calcium chloride 
that is more bioavailable than natural calcium salts in diet. In 
addition, this study showed increased isotope absorption after 
treatment with omeprazole which may be due to decrease 
in absorption of endogenous calcium. Finally, most of these 
subjects were overweight or obese and it is well known impact 
of obesity on calcium kinetics (21,22).
In a similar study Wright et al. investigated effects of 
esomeprazole on calcium absorption in 12 healthy subjects 
using TFCA (18). This study was of short duration and small 
sample size compared to our study. Furthermore, there is 
some evidence that indicates omeprazole may cause not only 
decreased calcium absorption but also a more generalized 
malabsorption syndrome (23-27).
Strengths and Weaknesses
Our study has a large sample size of almost young individuals. 
Duration of study and dosage of omeprazole are also 
acceptable. In addition, we include vit D status in this study 
which is the most important marker of calcium absorption. 
There are a number of limitations in our study too. Lack of 
measurement of bone resorption markers and high prevalence 
of vit D deficiency that may affect our results are the most 
important weaknesses of study. 
Although, there were no significant changes in serum PTH, 
25 OH vit D, Magnesium (Mg), Phosphate (P) and Uca/Ucr, 
we found a significant increase in serum ALP activity and 
a trend to decreasing serum calcium after one month of 
treatment with omeprazole which may be due to a decrease 
in intestinal absorption of calcium. However, due to high 
prevalence of vit D deficiency in this region consistent with 
our previous report (19), these results should be interpreted 
differently. As calcium plays a critical role in metabolic 
processes, its plasma concentrations should be kept in a 
narrow range. In the face of vit D deficiency -due to decreased 
intestinal calcium absorption- a compensatory rise in PTH 
causes near normalization of calcium albeit in the expense of 
bone resorption. In this situation omeprazole further impairs 
intestinal calcium absorption (by inducing hypochlorohydria), 
and causes a decrease however non-significant in serum 
calcium. On the other hand, further increase in parathyroid 
hormone leads to increase bone turnover which manifested as 
a significant rising in serum alkaline phosphatase.
In a study by Kocsis et al. treatment with 20 mg omeprazole 
daily for 2 weeks in children caused no significant changes 
in bone turnover (20). However, the study was too short to 
expect significant changes in bone take place. Furthermore, 
doses of omeprazole were lower and the patients were
DISCUSSION
and 13% respectively. Serum calcium, phosphate, alkaline 
phosphatase, magnesium and urinary calcium and creatinine 
were measured using available commercial kits.
Statistical analyses were performed using SPSS version 18 
(SPSS Inc., Chicago, Ill). Data were expressed as mean±SE 
for continuous variables and absolute numbers for categorical 
variables. Student t test and chi squared test were used for 
comparison of continuous and categorical variables between 
groups respectively. Paired sample t test and Wilcoxon sign 
rank test were used to compare variables at baseline and after 
intervention. P≤0.05 was set to be considered as significant.
The study protocol was approved by medical ethics 
committee of Zahedan University of Medical Sciences 
and informed written consent was obtained from all of 
participants.
RESULTS
Thirty adult individuals with mean age of 31.8 were included 
in this study. Female to male ratio was 2:1. Adherence 
to treatment was more than 96% and none of the patients 
reported significant side effects. Compared to control group 
mean serum phosphate was higher (P=0.001) and mean 
serum 25 OH vit D was lower (P=0.005) in patients (Table 
1). 98% of all of subjects were vit D deficient (Serum 25 
OH vit D < 50 nmol/l). Clinical and laboratory findings 
before and one month after treatment with omeprazole are 
depicted in Table 2. There were no significant changes in 
body mass index, serum concentrations of PTH, Phosphate, 
25 OH vit D and magnesium and urinary calcium/urinary 
creatinine (Uca/Ucr) before and after intervention. However, 
serum concentrations of alkaline phosphatase (ALP) 
were significantly higher after treatment with omeprazole 
(P=0.01). There was also a trend towards decrease in serum 
calcium after receiving omeprazole (P=0.057).
Table 1
Clinical and Laboratory characteristics of patients versus control
Abbreviations;
SE: standard error, M/F: male/female, BMI: body mass index, P: Phosphate, ALP: Alkaline Phosphatase, PTH: parathyroid 
hormone, 25 OH Vit D: 25 OH Vitamin D
Abbreviations;
SE: standard error, BMI: body mass index, P: Phosphate, ALP: Alkaline Phosphatase, PTH: parathyroid hormone, 25 OH 
Vit D: 25 OH Vitamin D, Ca: Calcium, Mg: Magnesium, Uca/Ucr: urinary calcium/urinary creatinine 
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Patients (N=30)
Mean±SE
Controls
(N=60)
Mean±SE
P
Sex (M/F)                                          10/20                                 20/40                                         1.0
Age (Years)                                       31.8±1.6                              31.4±1.0                                        0.8
BMI (Kg/m2)                                       24.3±0.8                              24.3±0.6                                        0.9
Serum
Calcium
(mmol/l)                                       
2.4±0.02                                  2.4±0.01                                0.5
Serum              P
(mmol/l)                                       
1.2±0.3                                    1.3±0.02                              0.001
Serum        ALP
(IU/L) 
172.8±9.4                                193.7±8.6                                0.1
Serum        PTH
(ng/l)
69.0±4.6                                  61.6±3.1                                0.1
Serum    25  OH
Vit D (nmol/l)
Serum    25  OH
Vit D (nmol/l)
29.7±4.5                                  15.7±0.5                              0.005
Table 2
Clinical and laboratory findings before and thirty days after treatment with omeprazole
Before intervention
(Mean±SE)
After intervention
(Mean±SE)
P
BMI (Kg/m2)                                       
Serum ALP (IU/L)                        
Serum Ca (mmol/l)                                      
24.3±0.88                             24.3±0.89                          0.8
172.8±9.4                            180.3±10.8                                    0.01
2.4±0.02                              2.4±0.01                                   0.057
Serum P (mmol/l)                                      1.2±0.3                             1.2±0.03                                       0.3
Serum PTH (ng/l) 69.0±4.6                             72.7±5.5                                       0.4
Serum Mg (mmol/l) 0.8±0.008                               0.8±0.01                                      0.4
Uca/Ucr (mmol/mmol) 0.08±0.009                              0.07±0.007                                    0.2
29.7±4.5                              26.4±2.7                                      0.1
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CONCLUSION
In conclusion, we showed that following thirty days, 
omeprazole affects bone and calcium metabolism through 
decreased intestinal calcium absorption. Further prospective 
studies with longer durations and more focus on vit D status 
are suggested.
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